Repertoire Immune Medicines Monday said it has entered strategic partnership with Bristol-Myers Squibb Company (BMY) to develop tolerizing vaccines for up to three autoimmune diseases.
As per the deal, Repertoire will receive an upfront payment of $65 million, up to $1.8 billion on achieving certain milestones, and tiered royalties.
Repertoire, by using its proprietary discovery platform DECODE will develop tolerizing vaccine candidates, while BMS will lead clinical development, regulatory affairs, and commercialization of them.
"This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease," said Torben Straight Nissen, CEO of Repertoire and Executive Partner of Flagship Pioneering.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.